Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, and osimertinib, have been the first line therapies for advanced NSCLC patients harboring sensitive EGFR mutation [2–4]. Here, EGFR is linked to non-small cell lung carcinoma.